Atea Pharmaceuticals (AVIR) Accumulated Depreciation (2019 - 2025)

Atea Pharmaceuticals' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 37.65% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 37.65% YoY), while the FY2025 annual figure was $1.5 million, up 37.65% from the prior year.
• Accumulated Depreciation was $1.5 million for Q4 2025 at Atea Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $1.5 million in Q4 2025 to a low of $161000.0 in Q4 2021.
• Historically, Accumulated Depreciation has averaged $749800.0 across 5 years, with a median of $689000.0 in 2023.
• The sharpest annual moves came in 2021 and 2023: Accumulated Depreciation gained 21.97% in 2021, then surged 152.38% in 2023.
• A 5-year view of Accumulated Depreciation shows it stood at $161000.0 in 2021, then jumped by 69.57% to $273000.0 in 2022, then soared by 152.38% to $689000.0 in 2023, then soared by 60.38% to $1.1 million in 2024, then soared by 37.65% to $1.5 million in 2025.
• The last three Accumulated Depreciation figures came in at $1.5 million (Q4 2025), $1.1 million (Q4 2024), and $689000.0 (Q4 2023), per Business Quant data.